EP0958824A2 — Olanzapine (zyprexa) in combination with fluoxetine (prozac), lithium or anticonvulsant for therapy of refractory depression
Assigned to Eli Lilly and Co · Expires 1999-11-24 · 26y expired
What this patent protects
The invention provides methods and compositions for the treatment of depressive states refractory to treatment with traditional anti-depressive therapies alone. These methods and compositions employ a compound having activity as an atypical antipsychotic and a serotonin reuptake …
USPTO Abstract
The invention provides methods and compositions for the treatment of depressive states refractory to treatment with traditional anti-depressive therapies alone. These methods and compositions employ a compound having activity as an atypical antipsychotic and a serotonin reuptake inhibitor. This invention also provides methods of providing rapid onset treatments of major depression which employing a compound having activity as an atypical antipsychotic and a serotonin reuptake inhibitor.
Drugs covered by this patent
- Abilify (aripiprazole) · Generic (originally Otsuka/BMS)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.